ibrutinib
Sponsor MRK · listed as MRK
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
ibrutinib is a clinical-stage drug asset sponsored by MRK, listed as MRK. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Dec 31, 2026 (day precision, medium confidence), tied to trial NCT01804686. The asset is in Phase 3 and currently recruiting, studied in Chronic Lymphocytic Leukemia. It appears across 9 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2026-12-31
As disclosedDec 31, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT01804686
PhasePHASE3
StatusRECRUITING
Lead sponsorJanssen Research & Development, LLC
Listed asMRK
Condition(s)Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma; Waldenstrom Macroglobulinemi…
All tracked catalysts for ibrutinib
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-31 | READOUT | medium | NCT01804686 |
| 2027-03-18 | READOUT | medium | NCT04212013 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More MRK catalysts